April 2, 2007 — Exenatide added to thiazolidinediones improved glycemic control and reduced body weight in some patients with type 2 diabetes, according to the results of a randomized, double-blind, placebo-controlled trial reported in the April 3 issue of the Annals of Internal Medicine.
"Exenatide therapy is effective in combination with metformin or sulfonylureas for treating type 2 diabetes," write Bernard Zinman, MD, from the University of Toronto in Ontario, Canada, and colleagues. "Thiazolidinediones (TZDs) also are commonly used, but the efficacy of exenatide with a TZD has not been reported."
From May 2004 to August 2005 at 490 sites in Canada, Spain, and the United States, 233 patients with type 2 diabetes suboptimally controlled with thiazolidinedione treatment (with or without metformin) were randomized to receive additional exenatide (n = 121) or placebo (n = 112). At baseline, mean glycated hemoglobin A1c (HbA1c) level was 7.9% ± 0.1%.
Patients received subcutaneous abdominal injections of 10 μg of exenatide or placebo twice daily, added to thiazolidinedione (with or without metformin), for 16 weeks. The main endpoint was change from baseline in HbA1c level, and other outcomes were fasting serum glucose level, body weight, self-monitored blood glucose level, and adverse events.
No comments:
Post a Comment